Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.
Search results for: treat-to-target
Non-Radiographic Axial Spondyloarthritis: A Review
SAN DIEGO—Alexis Ogdie-Beatty, MD, MSCE, associate professor of medicine, associate professor of epidemiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, gave a presentation on non-radiographic axial spondyloarthritis (nr-axSpA) in the Review Course prior to ACR Convergence 2023.
Concerning the Back: Updates in AS & nr-axSpA
During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.
How to Optimize Treatment for Aging Patients with Rheumatic Conditions
As patients with rheumatic musculoskeletal disease age, the number of medications they take may increase (i.e., polypharmacy), which can result in unwanted side effects and serious adverse effects. Lee et al. offer considerations and insights into caring for aging patients in a polypharmacy situation to better meet their health and lifestyle needs.
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
Treat to Target Lowers the Risk of Fracture in Patients with Gout
Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.
Measuring Up: A Review of the ACR-Owned Quality Measures
Since 2006, the Centers for Medicaid & Medicare Services (CMS) has increasingly driven clinicians to focus on and improve quality. Quality measures help clinicians measure how well they treat their patients. By tracking their performance, clinicians can identify opportunities to improve patient care while meeting federal reporting requirements. Breaking Down Quality Measures The CMS has…
Tigulixostat Promising for Patients with Gout & Hyperuricemia
In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 17
- Next Page »